Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 15.0

Eligibility Criteria:
Key Inclusion Criteria:~* Willing and able to provide written informed consent~* Chronic HCV infection~* Cirrhosis determination (liver biopsy may be required)~* Screening laboratory values within specified limits~* Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception~* Specific genotype, prior medical history, or concurrent disease as required by the specific study group~Key Exclusion Criteria:~* History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol~* Pregnant or nursing female, or male with pregnant female partner~* Clinical hepatic decompensation (ie, ascites, encephalopathy or variceal hemorrhage)~* Use of any prohibited concomitant medications~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF+RBV 24 Weeks (Cohort 1 Group 1) (Type: EXPERIMENTAL): Participants who previously received ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) plus ribavirin (RBV) for ≥ 12 weeks without achieving sustained virologic response at 12 weeks following treatment (SVR12) will receive LDV/SOF+RBV for 24 weeks.
- LDV/SOF+RBV 12 Weeks (Cohort 1 Group 2) (Type: EXPERIMENTAL): Participants who previously received a sofosbuvir-based regimen without achieving SVR12 were initially enrolled to receive LDV/SOF+RBV for 12 weeks (excluding participants who previously received LDV/SOF+RBV for ≥ 12 weeks). Participants who did not achieve sustained virologic response at 12 weeks were then moved to Cohort 1 Group 1.
- LDV/SOF 12 Weeks GT2 (Cohort 2 Group 1) (Type: EXPERIMENTAL): Participants with genotype 2 (GT2) HCV infection will receive LDV/SOF FDC for 12 weeks.
- LDV/SOF 8 Weeks GT2 (Cohort 2 Group 2) (Type: EXPERIMENTAL): Participants with GT2 HCV infection will receive LDV/SOF FDC for 8 weeks.
- LDV/SOF 12 Weeks GT1/GT2/GT4 (Cohort 3 Group 1) (Type: EXPERIMENTAL): Participants with genotypes 1 (GT1), 2 (GT2), or 4 (GT4) HCV infection and extrahepatic manifestations of chronic HCV infection will receive LDV/SOF FDC for 12 weeks.
- LDV/SOF+RBV 12 Weeks GT3 (Cohort 3 Group 2) (Type: EXPERIMENTAL): Participants with genotype 3 (GT3) HCV infection and extrahepatic manifestations of chronic HCV infection will receive LDV/SOF FDC plus RBV for 12 weeks.
- SOF/VEL+VOX 6 Weeks GT1 (Cohort 4) (Type: EXPERIMENTAL): Treatment-naive participants with GT1 HCV infection without cirrhosis will receive VOX only on Day 1 followed by sofosbuvir/velpatasvir (SOF/VEL) + voxilaprevir (VOX) for 6 weeks.
- SOF/VEL+VOX 4 Weeks GT1 (Cohort 5 Group 1) (Type: EXPERIMENTAL): Treatment-naive participants with GT1 HCV infection without cirrhosis will receive SOF/VEL+VOX for 4 weeks.
- SOF/VEL+VOX 6 Weeks GT1 (Cohort 5 Group 2) (Type: EXPERIMENTAL): Treatment-naive participants with GT1 HCV infection with cirrhosis will receive SOF/VEL+VOX for 6 weeks.
- SOF/VEL+VOX 6 Weeks GT3 (Cohort 5 Group 3) (Type: EXPERIMENTAL): Treatment-naive participants with GT3 HCV infection with cirrhosis will receive SOF/VEL+VOX for 6 weeks.
- SOF/VEL+VOX 8 Weeks GT1 (Cohort 5 Group 4) (Type: EXPERIMENTAL): Treatment-experienced participants with GT1 HCV infection with cirrhosis who were previously treated with pegylated interferon (Peg-IFN)+RBV will receive SOF/VEL+VOX for 6 weeks.
- SOF/VEL+VOX 8 Weeks GT3 (Cohort 5 Group 5) (Type: EXPERIMENTAL): Treatment-experienced participants with GT3 HCV infection with cirrhosis who were previously treated with Peg-IFN+RBV will receive SOF/VEL+VOX for 6 weeks.
- SOF/VEL+VOX 8 Weeks GT1 (Cohort 5 Group 6) (Type: EXPERIMENTAL): Treatment-experienced participants with GT1 HCV infection with or without cirrhosis who were previously treated with non-structural protein (NS3/4A) protease inhibitor (PI) will receive SOF/VEL+VOX for 6 weeks.
- SOF/VEL+VOX 6 Weeks GT1 (Cohort 5 Group 7) (Type: EXPERIMENTAL): Treatment-experienced participants with GT1 HCV infection with or without cirrhosis who were previously treated with direct-acting antivirals (DAA) will receive SOF/VEL+VOX for 6 weeks.
- SOF/VEL+VOX 8 Weeks GT3 (Cohort 5 Group 8) (Type: EXPERIMENTAL): Treatment-experienced participants with GT3 HCV infection with or without cirrhosis who were previously treated with DAA will receive SOF/VEL+VOX for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete